Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Bone Diseases, Metabolic 3Prostatic Neoplasms 2Osteoporosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1Lung Neoplasms 1Leukemia 1Esophageal Neoplasms 1Dwarfism, Pituitary 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Rituximab 173Cyclophosphamide 156Vincristine 72fludarabine phosphate 71Etoposide 68Doxorubicin 68Prednisone 66Filgrastim 58Methotrexate 52Cytarabine 51fludarabine 49Melphalan 48Busulfan 47Tacrolimus 41Whole-Body Irradiation 39Mycophenolic Acid 39Granulocyte Colony-Stimulating Factor 37Antilymphocyte Serum 31Peripheral Blood Stem Cell Transplantation 30Radiotherapy 27Lenalidomide 25Dexamethasone 25Carmustine 23Stem Cell Transplantation 22Cyclosporine 22Bortezomib 22Gemcitabine 20Bendamustine Hydrochloride 20ibritumomab tiuxetan 19Alemtuzumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma × Risedronic Acid × Clear all
NCT00452439 2020-12-28

A Study of Actonel for the Prevention of Bone Loss

M.D. Anderson Cancer Center

Phase 3 Completed
72 enrolled 8 charts
LymphoidOther hematologic neoplasm

Bone Diseases, Metabolic, Leukemia, Lymphoma, Osteoporosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡